Showing 37 to 48 of 152 results
Sandoz CEO Rejects US Tariffs, Prioritizes European Investment
Sandoz CEO Richard Saynor criticizes US pharmaceutical tariffs, citing their counterproductive impact on investment and advocating for stronger regulations on originator companies to foster competition. Sandoz is instead heavily investing in Slovenia, exceeding \$1.1 billion by 2029.
Sandoz CEO Rejects US Tariffs, Prioritizes European Investment
Sandoz CEO Richard Saynor criticizes US pharmaceutical tariffs, citing their counterproductive impact on investment and advocating for stronger regulations on originator companies to foster competition. Sandoz is instead heavily investing in Slovenia, exceeding \$1.1 billion by 2029.
Progress
40% Bias Score
AstraZeneca's Potential US Relocation Could Cost UK £1 Billion Annually
AstraZeneca, a £161 billion pharmaceutical company, is considering moving its stock market listing from London to Wall Street due to concerns over UK drug pricing and regulatory issues, potentially costing the UK Treasury £1 billion annually in taxes and impacting the UK's economic growth.
AstraZeneca's Potential US Relocation Could Cost UK £1 Billion Annually
AstraZeneca, a £161 billion pharmaceutical company, is considering moving its stock market listing from London to Wall Street due to concerns over UK drug pricing and regulatory issues, potentially costing the UK Treasury £1 billion annually in taxes and impacting the UK's economic growth.
Progress
68% Bias Score
China Launches Commercial Insurance Catalog for Innovative Drugs
China's healthcare authority announced a new commercial insurance catalog for innovative drugs to expand access to advanced treatments beyond the capacity of the basic medical insurance program, which covered 1.326 billion people in 2022, spending 2.97 trillion yuan.
China Launches Commercial Insurance Catalog for Innovative Drugs
China's healthcare authority announced a new commercial insurance catalog for innovative drugs to expand access to advanced treatments beyond the capacity of the basic medical insurance program, which covered 1.326 billion people in 2022, spending 2.97 trillion yuan.
Progress
36% Bias Score
EU Pharma Industry Opposes Retaliatory Tariffs Amid US Drug Import Levy Threat
The European pharmaceutical industry urges the EU against retaliatory tariffs on US drugs, fearing negative consequences for both sides and higher patient costs; the EU faces a July 9th deadline for trade deals with the US, and non-tariff barriers also hamper European competitiveness.
EU Pharma Industry Opposes Retaliatory Tariffs Amid US Drug Import Levy Threat
The European pharmaceutical industry urges the EU against retaliatory tariffs on US drugs, fearing negative consequences for both sides and higher patient costs; the EU faces a July 9th deadline for trade deals with the US, and non-tariff barriers also hamper European competitiveness.
Progress
48% Bias Score
Moderna Stock Plummets 80% on Reduced COVID-19 Vaccine Sales
Moderna's stock price has fallen over 80% in the last year due to an 83% decrease in revenue from its COVID-19 vaccine, dropping from $18.9 billion in 2022 to $3.1 billion over the last twelve months, and projected to reach $2.1 billion in 2025; this is primarily because of reduced demand as the pan...
Moderna Stock Plummets 80% on Reduced COVID-19 Vaccine Sales
Moderna's stock price has fallen over 80% in the last year due to an 83% decrease in revenue from its COVID-19 vaccine, dropping from $18.9 billion in 2022 to $3.1 billion over the last twelve months, and projected to reach $2.1 billion in 2025; this is primarily because of reduced demand as the pan...
Progress
56% Bias Score
Medicare Drug Price Negotiations Continue Under Trump Administration
The Trump administration is continuing Medicare's drug price negotiations begun under Biden, with initial offers sent to Novo Nordisk and Amgen for 15 drugs; lower prices are expected to start in January 2027.
Medicare Drug Price Negotiations Continue Under Trump Administration
The Trump administration is continuing Medicare's drug price negotiations begun under Biden, with initial offers sent to Novo Nordisk and Amgen for 15 drugs; lower prices are expected to start in January 2027.
Progress
36% Bias Score
High Costs, Inconsistent Coverage Limit Access to Popular Obesity Drugs
High prices and inconsistent insurance coverage limit access to the popular obesity medications Wegovy and Ozempic, despite falling costs and some employer-sponsored plans expanding coverage; the medications cost around $500 per month without insurance, forcing doctors to find creative solutions and...
High Costs, Inconsistent Coverage Limit Access to Popular Obesity Drugs
High prices and inconsistent insurance coverage limit access to the popular obesity medications Wegovy and Ozempic, despite falling costs and some employer-sponsored plans expanding coverage; the medications cost around $500 per month without insurance, forcing doctors to find creative solutions and...
Progress
40% Bias Score
AstraZeneca Weighs US Relocation Amid UK Disputes
AstraZeneca, facing disagreements with UK authorities over drug pricing and support, is considering moving its stock market listing and potentially its headquarters to the US, jeopardizing Britain's industrial strategy and London's financial standing.
AstraZeneca Weighs US Relocation Amid UK Disputes
AstraZeneca, facing disagreements with UK authorities over drug pricing and support, is considering moving its stock market listing and potentially its headquarters to the US, jeopardizing Britain's industrial strategy and London's financial standing.
Progress
56% Bias Score
AstraZeneca Weighs US Stock Market Listing, Threatening London's Status
AstraZeneca, the UK's largest listed firm, is considering moving its stock market listing to the US due to frustrations with UK regulations and pricing disputes, potentially causing significant damage to the London Stock Exchange.
AstraZeneca Weighs US Stock Market Listing, Threatening London's Status
AstraZeneca, the UK's largest listed firm, is considering moving its stock market listing to the US due to frustrations with UK regulations and pricing disputes, potentially causing significant damage to the London Stock Exchange.
Progress
56% Bias Score
EU Health Funding Faces Uncertain Future in Upcoming Budget
Concerns are rising about the future of the EU4Health program (€5.3 billion) in the upcoming EU budget, with fears that increased defense spending could lead to its merger or elimination, impacting various health initiatives and potentially worsening health outcomes.
EU Health Funding Faces Uncertain Future in Upcoming Budget
Concerns are rising about the future of the EU4Health program (€5.3 billion) in the upcoming EU budget, with fears that increased defense spending could lead to its merger or elimination, impacting various health initiatives and potentially worsening health outcomes.
Progress
56% Bias Score
MSF's Secret Drug Deals Undermine Transparency Campaign
Doctors Without Borders (MSF) signed non-disclosure agreements (NDAs) with pharmaceutical companies, including Bayer, to obtain medicines for low-income countries, contradicting their public advocacy for drug price transparency, due to the power imbalance in supply negotiations.
MSF's Secret Drug Deals Undermine Transparency Campaign
Doctors Without Borders (MSF) signed non-disclosure agreements (NDAs) with pharmaceutical companies, including Bayer, to obtain medicines for low-income countries, contradicting their public advocacy for drug price transparency, due to the power imbalance in supply negotiations.
Progress
44% Bias Score
Pharmaceutical Industry Fails to Produce Female Viagra, Exposing Gendered Biases in Research
The pharmaceutical industry's pursuit of a female Viagra, despite significant investment and research since 1998, has yielded no comparable product. This failure highlights the significant differences in male and female sexual response and research bias.
Pharmaceutical Industry Fails to Produce Female Viagra, Exposing Gendered Biases in Research
The pharmaceutical industry's pursuit of a female Viagra, despite significant investment and research since 1998, has yielded no comparable product. This failure highlights the significant differences in male and female sexual response and research bias.
Progress
56% Bias Score
Showing 37 to 48 of 152 results